Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
Ann OncolMay 29, 2026 (epub)
A T Shaw, B J Solomon, E Felip et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase III CROWN study evaluated lorlatinib versus crizotinib in treatment-naive patients with advanced ALK-positive non-small-cell lung cancer (NSCLC). After 7 years, lorlatinib demonstrated a median progression-free survival (PFS) not reached, compared to 9.1 months for crizotinib, with a 7-year PFS of 55% versus 3%.
Key findings
- Median PFS was not reached with lorlatinib, while crizotinib had a median PFS of 9.1 months.
- 7-year PFS rates were 55% for lorlatinib and 3% for crizotinib.
- Patients without a PFS event at 24 months on lorlatinib had a 79% probability of survival without progression at year 7.
- No new intracranial progression events occurred after 30 months on lorlatinib.
Why it matters
The findings highlight the potential of lorlatinib to provide long-term disease control in advanced ALK-positive NSCLC, suggesting a shift towards managing this condition as a chronic illness.